Hydrogenology
Source-linked study record

Electrolyzed hydrogen-rich water for oxidative stress suppression and improvement of insulin resistance: a multicenter prospective double-blind randomized control trial

Ogawa S, Ohsaki Y, Shimizu M, et al. · Diabetology International. 2022;13(1):209–219.

HumanH₂-rich waterPublished 2022Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Human

Population or model

Japanese adults with type 2 diabetes, preserved insulin secretion and no insulin therapy.

Intervention and dose

Participants drank 1,500–2,000 mL/day of water produced at home with a TRIM ION HYPER device. · The pH setting was increased during the first week and maintained at pH 8.5–9.9 thereafter. The article does not report a numeric dissolved-H₂ concentration at preparation or consumption.

Duration

3 months.

Reported result

The primary outcome was null: HOMA-IR changed by -0.27 in the EHW arm and +0.04 with filtered water, between-group p=0.282; percentage-change p=0.638. Most oxidative-stress and metabolic outcomes were also null. Lactate decreased within the EHW arm, while subgroup and correlation findings were exploratory. No EHW-related adverse effect was observed.

Main limitation

Small trial with six dropouts, baseline differences and many exploratory subgroup/correlation analyses after a null primary endpoint. The trial was conducted jointly with Nihon Trim; two authors had Nihon Trim affiliations and the company supplied intervention and placebo devices.

Evidence and classification

What kind of evidence is this?

Evidence type

Human

Reported design

Multicenter prospective double-blind randomized controlled parallel trial

Research topic

Metabolic and lipid health

Administration form

H₂-rich water

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

Japanese adults with type 2 diabetes, preserved insulin secretion and no insulin therapy.

Sample

49 randomized: electrolyzed hydrogen-rich water n=25 and filtered water n=24; 43 completed and were analyzed (23 and 20).

Duration

3 months.

Intervention

Participants drank 1,500–2,000 mL/day of water produced at home with a TRIM ION HYPER device.

Hydrogen form

H₂ dissolved in electrolyzed drinking water — H₂ only as the therapeutic gas, not Brown's gas.

Dose or H₂ specification

The pH setting was increased during the first week and maintained at pH 8.5–9.9 thereafter. The article does not report a numeric dissolved-H₂ concentration at preparation or consumption.

Comparator

Filtered water from outwardly identical home devices; allocation and data management were performed by a third party and participants and installers were blinded.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Primary HOMA-IR; glucose-tolerance, oxidative-stress, antioxidant, hematology, biochemical and safety measures.

Reported result

The primary outcome was null: HOMA-IR changed by -0.27 in the EHW arm and +0.04 with filtered water, between-group p=0.282; percentage-change p=0.638. Most oxidative-stress and metabolic outcomes were also null. Lactate decreased within the EHW arm, while subgroup and correlation findings were exploratory. No EHW-related adverse effect was observed.

Extraction completeness

The complete PMC article, supplementary material, trial flow, three-month outcome table, adverse events and commercial involvement were checked; the null primary result is stated explicitly.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Small trial with six dropouts, baseline differences and many exploratory subgroup/correlation analyses after a null primary endpoint. The trial was conducted jointly with Nihon Trim; two authors had Nihon Trim affiliations and the company supplied intervention and placebo devices.

Applies directly to

Adults with type 2 diabetes not using insulin who matched the Japanese trial criteria; not evidence of improved insulin resistance in the overall trial population.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 35059257 · DOI: 10.1007/s13340-021-00524-3

Publisher access

Free full article on PubMed Central.

Extraction basis

PMC full article, PubMed record and registry metadata; full-text and article-status check completed 8 August 2026.

Last reviewed

10 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.